Benitec Biopharma Inc. BNTC
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -6.07% | -17.60% | 39.17% | 191.61% | 242.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.74% | -11.43% | 23.80% | 69.28% | 77.25% |
| Operating Income | -46.74% | 11.43% | -23.80% | -69.28% | -77.25% |
| Income Before Tax | -45.47% | 17.70% | -23.92% | -77.21% | -86.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -45.47% | 17.70% | -23.92% | -77.21% | -86.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.47% | 17.70% | -23.92% | -77.21% | -86.55% |
| EBIT | -46.74% | 11.43% | -23.80% | -69.28% | -77.25% |
| EBITDA | -46.77% | 11.45% | -23.83% | -69.79% | -77.83% |
| EPS Basic | -21.13% | 35.67% | -0.43% | -19.02% | -17.01% |
| Normalized Basic EPS | -21.09% | 35.69% | 7.05% | -18.96% | -17.08% |
| EPS Diluted | -21.13% | 35.67% | -0.43% | -19.02% | -17.01% |
| Normalized Diluted EPS | -21.09% | 35.69% | 7.05% | -18.96% | -17.08% |
| Average Basic Shares Outstanding | 20.12% | 27.95% | 23.39% | 48.91% | 59.36% |
| Average Diluted Shares Outstanding | 20.12% | 27.95% | 23.39% | 48.91% | 59.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |